The innate immune sensor RIG-I responds to infection by binding to viral double-stranded RNA (dsRNA). In this issue of Cell, Kowalinski et al. (2011) and Luo et al. (2011) reveal the structure of RIG-I, and in combination with functional analyses, they show how RIG-I recognizes viral RNA to initiate signaling and a type I interferon response.
The innate immune response to viral infection is initiated by the recognition of viral nucleic acids in an infected cell (O'Neill and Bowie, 2010) . RIG-I is a key intracellular receptor that detects viral doublestranded RNA (dsRNA) and launches a signaling pathway that culminates in the induction of antiviral type I interferons. RIG-I is activated by a number of viruses, including measles, influenza, and hepatitis C, and has a nonredundant role in antiviral immunity (Kato et al., 2006) . Two papers in this issue of Cell (Kowalinski et al., 2011; Luo et al., 2011) describe precisely how RIG-I works. The studies support a model in which RIG-I functions as a nanomachine that responds to binding of ATP and dsRNA with a conformational change, which one author terms a ''powerstroke,'' to unleash the caspase activation and recruitment domains (CARDs) for downstream signaling (Figure 1) .
RIG-I is a superfamily 2 (SF2) helicase that features two N-terminal tandem CARDs, a DExH-box helicase domain, and a C-terminal domain (CTD), which in the resting state has been shown to repress the function of RIG-I (Figure 1 ). RNA binding activates RIG-I, and it associates with blunt end 5 0 triphosphate RNA (18-20 nucleotides long), as well as with longer dsRNA (greater than 200 nucleotides) (Hornung et al., 2006; Kato et al., 2008) . RNA binds to both the CTD and the helicase domain. Binding is thought to stimulate the ATPase activity of the helicase domain, triggering a conformational change that exposes the masked CARDs (Gee et al., 2008) . The available CARDs then recruit the E3-ligase tripartite motifcontaining 25 (TRIM25) that modifies the domains with K63-linked polyubiquitin chains. Unanchored K63-linked ubiquitin chains also associate with the CARDs (Zeng et al., 2010) . The formation of these CARD-associated chains is essential for recruitment of the adaptor protein MAVS, which aggregates in the outer mitochondrial membrane and ultimately promotes the induction of type I interferons.
The importance of the RIG-I pathway can be seen from the fact that viral proteins target it in order to evade the host immune response (Bowie and Unterholzner, 2008) . For example, NS2 protein of respiratory syncytial virus binds RIG-I directly, NS1 from influenza interferes with TRIM25, and the hepatitis C virus protease cleaves and inactivates MAVS.
To crack the structure of RIG-I, Cusack and colleagues (Kowalinski et al., 2011) focused on constructs from duck RIG-I (dRIG-I) representing the free, resting (or autorepressed), and activated states, whereas Pyle and coworkers looked at human RIG-I lacking the CARDs, which forms a more intermediate activated state (Luo et al., 2011) . The overall structures, perhaps unsurprisingly, reveal many similarities. A highly interesting feature is in the helicase domain, known to contain two helicase RecA-like domains (Hel1 and Hel2) together with a domain inserted into Hel2, termed Hel2i ( Figure 1 ). This key region forms a long ''elbow''-like structure that extends from Hel2, folds back to interact with Hel1, and then connects to the CTD seen for the human protein and in one of the duck RIG-I structures. From sequence homology, this arrangement is likely to be conserved with the other RIG-I-like receptors, MDA-5 and LGP2. In the free state seen for the dRIG-I helicase domain in the absence of RNA and ATP, the domain is open and flexible (Luo et al., 2011) . The CTD would presumably be available to interact with RNA. Initial capture of 5 0 triphosphate dsRNA by the CTD would then increase the concentration of dsRNA in the vicinity of the helicase. Subsequent cooperative binding of dsRNA and ATP causes a dramatic change in conformation, with the three helicase subdomains all moving relative to each other (Kowalinski et al., 2011) . This rearrangement brings Hel1 and Hel2 into close contact, creating a high-affinity complex between dsRNA and the helicase domain with a common conformation appearing in both studies (Kowalinski et al., 2011; Luo et al., 2011) .
The structures also reveal a wealth of information on the interaction between the proteins and dsRNA. RIG-I completely surrounds the dsRNA molecule and encloses it in a network of interactions. Both dRIG-I and the human protein cover a region of 9-10 bp along the dsRNA. Hel1 faces the minor groove of the dsRNA and interacts with the RNA backbone of both strands, and the Hel2i domain contributes significantly to RNA binding. A notable comparator here is TLR3, another important antiviral receptor. TLR3 binds dsRNA as a dimer, with each monomer binding to one side of the RNA duplex (Liu et al., 2008) . Also of note is the observation that human RIG-I dimers are able to interact with dsRNA that is 18 bp long, with one RIG-I interacting with the first nine nucleotides, and another RIG-I interacting with the next nine (Luo et al., 2011) . This interaction between the RIG-I monomers is driven by the RNA template rather than by direct dimerization of the proteins.
The ''elbow''-like structure referred to above, which connects Hel1 to the CTD, can be described as a ''pincer'' that grips an a-helical shaft that extends from Hel1 (Luo et al., 2011) . The authors suggest that this extension functions in a similar fashion to the camshaft of an engine, facilitating mechanical communication between Hel1, Hel2, and the CTD and coordinating the structural rearrangement in the protein that occurs during the ''powerstroke'' that follows ATP binding. The pincer is proposed to be able to open and close, or rotate around the shaft, altering the orientations of Hel1 to Hel2 and CTD to Hel1. Kowalinski et al. (2011) see this region as a bridging element that contacts Hel1, although the specific interactions differ. In either case, changes in this structural element upon activation would contribute to transmission of the signal (RNA and ATP binding) to the CARDs, releasing them from their autorepressed state.
How does the conformational change in the helicase domain lead to the release of the CARDs for interaction with MAVS? In the resting state structure (Kowalinski et al., 2011) , CARD1 and CARD2 interact in a head-to-tail manner, with the head of CARD1 interacting with the tail of CARD2, forming a rigid functional unit. In this state, both CARDs interact with Hel2i. CARD2's contact with Hel2i would block access for TRIM or K63-linked polyubiquitin in this autorepressed state. The structure of the activated complex (Kowalinski et al., 2011) shows that the conformational change in the helicase domain releases CARD2 from this constraint. Effectively, the high-affinity ATP binding to the helicase leads to a 55 residue long linker between CARD2 and the helicase domain pushing the CARDs out of the structure as a powerstroke (Figure 1 ). The modified CARDs would then be able to interact with MAVS. Finally, ATP hydrolysis would loosen the helicase domain, reverting the CARDs-now deubiquitinated-to the autorepressed state.
Structural insight into the architecture of RIG-I and the movements that enable it to respond effectively to dsRNA triggers will have far-reaching implications. The structures of RIG-I reported here provide us with the first detailed account of a protein in the SF2 Dicer-RIG-I clade. They may therefore also prove useful in the effort to uncover how Dicer functions in the generation of miRNAs. Moreover, given the role of RIG-I in antiviral immunity, the structures also offer a starting point for the effort to develop inhibitors or activators of RIG-I. Overactivation of RIG-I could be important in viral pathology, including hepatitis C and influenza, and inhibitors could have clinical utility in treating these and other infections. Specific activation on the other hand could be useful in vaccine adjuvancy. These two studies open the door for structural analyses of the many other nucleic acid-sensing proteins, which will provide us with detailed insight on the molecular basis of antiviral innate immunity. (B) Activation of RIG-I. In the inactive state, the RIG-I CARDs are sequestered by the helicase domains and are not available for signaling. The CTD has high affinity for 5 0 triphosphate dsRNA and can capture viral RNA containing this motif, increasing the local concentration of dsRNA and favoring its cooperative binding with ATP to the helicase domains. Conformational changes upon RNA and ATP binding exert a powerstroke, leading to a ligand-bound, closed helicase complex. The conformational switch pushes the tandem CARDs away from the helicase complex, making them available to recruit TRIM25, which leads to the local generation of CARD-associated free K63-linked polyubiquitin chains, an event known to be essential for engagement of MAVS and subsequent downstream signaling to type I interferon induction. RNA-mediated RIG-I dimerization is also likely important for activation (not shown).
Hornung, V., Ellegast, J., Kim, S., Brzó zka, K.,Opioids such as morphine numb pain but often concomitantly induce itch. Liu et al. (2011) now separate the sensation of itch from opioid-induced analgesia, showing that in a subset of spinal neurons, morphine directly induces itch by signaling through a heteromer of opioid-and itch-mediating G protein-coupled receptors.
Itch, or pruritus, is defined as an unpleasant sensation that elicits the desire or reflex to scratch (Ikoma et al., 2006) . Itch occurs under many pathological conditions, such as atopic dermatitis, and is a common side effect of many drugs, including antibiotics, antifungal drugs, and narcotic pain medications (Reich et al., 2009) . For example, the malaria drug chloroquine induces itch by acting on peripheral sensory neurons via a G protein-coupled receptor, MrgprA3 (Liu et al., 2009 ). Another example is opioidinduced itch, which is most severe when opioids are administered directly into the spinal column via an epidural injection. Spinal opioid-induced itch has been assumed to arise as a consequence of pain inhibition, but the underlying mechanism has been largely unknown. In this issue of Cell, a study by Liu et al. provides compelling evidence that spinal opioidinduced itch is evoked independently of opioid-induced analgesia by signaling through an opioid receptor splice isoform expressed in itch-mediating spinal neurons (Liu et al., 2011) .
The distinct sensations of itch and pain are evoked by different stimuli and induce discrete responses (scratching versus withdrawal). However, interactions between these two sensations are well known; various types of noxious stimuli are able to inhibit itch, and inhibition of pain may evoke itch (Ikoma et al., 2006) . It has been postulated that pain signals have a dominant inhibitory effect on itch signals. This selectivity model is supported by recent studies reporting attenuated pain and enhanced itch behaviors in mice whose neurotransmission is inactivated in subsets of nociceptive sensory neurons (Patel and Dong, 2010) . As the selectivity model predicts, opioidinduced itch has been thought to arise indirectly as a consequence of opioidinduced analgesia.
The new study by Liu et al. explores the molecular basis of morphine-induced scratching (MIS) and analgesia (MIA) in mice. Previous experiments had established that both MIS and MIA are mediated by m-opioid receptor (MOR) (Loh et al., 1998; Matthes et al., 1996) . The mouse Oprm gene encodes many splice isoforms of MOR (Pan, 2005) . Liu and colleagues used exon-specific siRNA knockdown in vivo and identified MOR1D and MOR1 isoforms to be specifically required for itch and analgesia, respectively. MOR1D is coexpressed with the gastrinreleasing peptide receptor (GRPR), a G protein-coupled receptor that marks spinal cord neurons required for the sensation of itch (Sun and Chen, 2007; Sun et al., 2009 ). Both pharmacological and genetic knockdown of GRPR resulted in specific attenuation of MIS without affecting MIA (Figure 1 ). The authors show that MOR1D and GRPR physically interact. Upon further investigation, they provide functional evidence that these two receptors cross-activate in only one direction: MOR1D activation by morphine results in GRPR activation, but not vice versa. Providing potential therapeutic insight, Liu and colleagues show that a unique C-terminal peptide of MOR1D attached to a plasma membrane-permeating signal competes with endogenous MOR1D for physical interaction with
